7,598 Shares in IQVIA Holdings Inc. (NYSE:IQV) Acquired by Jaffetilchin Investment Partners LLC

Jaffetilchin Investment Partners LLC acquired a new stake in IQVIA Holdings Inc. (NYSE:IQV) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 7,598 shares of the medical research company’s stock, valued at approximately $1,493,000.

Several other hedge funds and other institutional investors also recently made changes to their positions in the business. Synergy Asset Management LLC bought a new stake in shares of IQVIA during the 4th quarter valued at $33,000. Lee Danner & Bass Inc. purchased a new stake in IQVIA during the 4th quarter valued at about $44,000. Zions Bancorporation N.A. boosted its stake in shares of IQVIA by 55.2% during the fourth quarter. Zions Bancorporation N.A. now owns 239 shares of the medical research company’s stock valued at $47,000 after purchasing an additional 85 shares during the period. Versant Capital Management Inc grew its holdings in IQVIA by 46.0% in the 4th quarter. Versant Capital Management Inc now owns 295 shares of the medical research company’s stock worth $58,000 after acquiring an additional 93 shares during the last quarter. Finally, SBI Securities Co. Ltd. purchased a new position in IQVIA during the 4th quarter valued at about $60,000. 89.62% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several brokerages have commented on IQV. Stifel Nicolaus lowered their price objective on shares of IQVIA from $273.00 to $261.00 and set a “buy” rating for the company in a report on Friday, February 7th. Mizuho reduced their price objective on shares of IQVIA from $242.00 to $210.00 and set an “outperform” rating for the company in a research note on Wednesday. Barclays restated an “equal weight” rating and set a $170.00 target price (down previously from $235.00) on shares of IQVIA in a research note on Thursday. Royal Bank of Canada restated an “outperform” rating and set a $270.00 price target on shares of IQVIA in a research note on Monday, February 10th. Finally, Truist Financial dropped their price target on shares of IQVIA from $263.00 to $216.00 and set a “buy” rating on the stock in a research note on Thursday. Six research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, IQVIA currently has a consensus rating of “Moderate Buy” and an average price target of $241.50.

IQVIA Price Performance

IQVIA stock opened at $145.40 on Friday. The business has a fifty day moving average of $182.32 and a two-hundred day moving average of $199.64. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.84 and a current ratio of 0.84. The company has a market cap of $25.64 billion, a P/E ratio of 19.39, a price-to-earnings-growth ratio of 1.99 and a beta of 1.46. IQVIA Holdings Inc. has a one year low of $135.97 and a one year high of $252.88.

IQVIA (NYSE:IQV) last announced its earnings results on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. As a group, analysts predict that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.